Discover undervalued stocks with Eulerpool.

Bio-Techne Stock TECH

Price

0
Today +/-
-0
Today %
-0 %

Bio-Techne stock price

Loading chart...
Weekly
Details

Price

Overview

The Quote Chart provides detailed and dynamic insights into the Bio-Techne stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Bio-Techne stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Bio-Techne stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Bio-Techne's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Bio-Techne Stock Price History

DateBio-Techne Price
8/21/20250 undefined
8/20/202554.34 undefined
8/19/202554.62 undefined
8/18/202553.50 undefined
8/15/202553.83 undefined
8/14/202553.68 undefined
8/13/202554.25 undefined
8/12/202552.84 undefined
8/11/202550.37 undefined
8/8/202550.20 undefined
8/7/202549.67 undefined
8/6/202549.03 undefined
8/5/202554.72 undefined
8/4/202554.89 undefined
7/31/202554.89 undefined
7/30/202554.73 undefined
7/29/202557.71 undefined
7/28/202557.87 undefined
7/27/202558.55 undefined
7/25/202559.30 undefined
7/24/202558.95 undefined
7/23/202555.29 undefined
7/22/202553.22 undefined

Bio-Techne Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Details

Revenue, EBIT and Profit

Understanding Revenue, EBIT, and Income

Gain insights into Bio-Techne, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Bio-Techne from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Bio-Techne’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Bio-Techne. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Bio-Techne’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Bio-Techne’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Bio-Techne’s growth potential.

Bio-Techne Revenue, EBIT and net profit per share

DateBio-Techne RevenueBio-Techne EBITBio-Techne Net Income
2031e2.19 B undefined0 undefined0 undefined
2030e1.75 B undefined748.68 M undefined469.01 M undefined
2029e1.58 B undefined598.33 M undefined450.97 M undefined
2028e1.5 B undefined509.55 M undefined425.88 M undefined
2027e1.43 B undefined471.36 M undefined387.49 M undefined
2026e1.31 B undefined416.1 M undefined341.26 M undefined
2025e1.24 B undefined384.31 M undefined313.56 M undefined
20241.16 B undefined248.46 M undefined168.07 M undefined
20231.14 B undefined293.6 M undefined285.2 M undefined
20221.11 B undefined298.2 M undefined271.9 M undefined
2021931 M undefined244.9 M undefined140.3 M undefined
2020738.7 M undefined150.7 M undefined229.1 M undefined
2019714 M undefined149 M undefined96 M undefined
2018643 M undefined161 M undefined126.2 M undefined
2017563 M undefined146.4 M undefined76.1 M undefined
2016499 M undefined153.4 M undefined104.5 M undefined
2015452.2 M undefined151.5 M undefined107.7 M undefined
2014357.8 M undefined159.8 M undefined110.9 M undefined
2013310.6 M undefined158.5 M undefined112.6 M undefined
2012314.6 M undefined170.5 M undefined112.3 M undefined
2011290 M undefined165.8 M undefined112.3 M undefined
2010269 M undefined156.3 M undefined109.8 M undefined
2009264 M undefined150.8 M undefined105.2 M undefined
2008257.4 M undefined144.3 M undefined103.6 M undefined
2007223.5 M undefined124.2 M undefined85.1 M undefined
2006202.6 M undefined108.5 M undefined73.4 M undefined
2005178.7 M undefined97.8 M undefined66.1 M undefined

Bio-Techne Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (B)
REVENUE GROWTH (%)
GROSS MARGIN (%)
GROSS INCOME (M)
NET INCOME (M)
NET INCOME GROWTH (%)
DIV. ()
DIV. GROWTH (%)
SHARES (M)
DOCUMENTS
198719881989199019911992199319941995199619971998199920002001200220032004200520062007200820092010201120122013201420152016201720182019202020212022202320242025e2026e2027e2028e2029e2030e2031e
0.010.010.010.020.020.020.030.040.050.050.060.070.090.10.120.130.150.160.180.20.220.260.260.270.290.310.310.360.450.50.560.640.710.740.931.111.141.161.241.311.431.51.581.752.19
-22.229.0925.0026.6715.7927.2742.8617.5014.8911.1111.6734.3314.4411.6513.0411.5411.0310.5613.4810.4015.252.721.897.818.28-1.2715.1626.6110.4012.8314.2111.043.3626.1518.692.812.026.995.489.405.105.2510.5524.86
44.4454.5550.0053.3347.3750.0053.5757.5061.7064.8168.3370.1570.0074.7674.7875.3875.1778.2679.2177.2378.9279.3878.7979.5577.5975.8074.5270.3167.9267.3366.4367.1966.2565.4567.8868.4267.6966.3562.0258.7953.7451.1348.5843.9435.19
4668911152329354147637786981091261411561762042082142252382312513073363744324734836327567697690000000
0001124568101516263427455266738510310510911211211211010710476126962291402712851683133413874254504690
-----100.00100.0025.0020.0033.3325.0050.006.6762.5030.77-20.5966.6715.5626.9210.6116.4421.181.943.812.75---1.79-2.73-2.80-26.9265.79-23.81138.54-38.8693.575.17-41.0586.318.9513.499.825.884.22-
----------------------0.250.260.270.280.300.310.320.320.320.320.320.320.320.320.320.400.320.820.940.981.071.11-
0000000000000000000000043.853.77.143.333.230000000025-20156.2514.634.269.183.740
115.6129.2132.9135138.6147151.1152.3152.3155.5155.7156.9165.5168.8170.7170.1168.1166.8163.7158.4158.1157151.6149.4148.7148147.6148148.9149.3150152.2155.6157.6161.9164.1161.9160.770000000
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
Details

Keystats

Revenue and Growth

The Bio-Techne Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Bio-Techne is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETS
CASH BALANCE (M)
RECEIVABLES (M)
OTHER REC. (M)
INVENTORIES (M)
OTHER CURRENT LIAB. (M)
CURRENT ASSETS (M)
TANGIBLE ASSETS (M)
LONG-T. INVEST. (M)
LONG-T. REC. (M)
INTANGIBLE ASSETS (M)
GOODWILL (M)
OTHER NON-CURRENT ASSETS (M)
NON-CURRENT ASSETS (B)
TOTAL ASSETS (B)
LIABILITIES
COMMON STOCK (M)
ADDITIONAL PAID-IN CAPITAL (M)
RETAINED EARNINGS (B)
OTHER EQUITY (M)
UNREAL. GAINS/LOSSES (M)
EQUITY (B)
LIABILITIES (M)
PROVISIONS (M)
OTHER SHORT-TERM LIAB. (M)
SHORT-TERM DEBTS (M)
LONG-TERM DEBT PORTION (M)
SHORT-TERM REC. (M)
LONG-T. LIAB. (M)
DEFERRED TAXES (M)
OTHER LIAB. (M)
LONG-T. LIABILITIES (M)
DEBT (M)
TOTAL CAPITAL (B)
198919901991199219931994199519961997199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024
                                                                       
11.325.97.810.915.919.224.841.429.159.897.197.1118.893.797.1108.8164.8206.3202.9138.8140.8269332.9363.4110.995.8157.7181.8166270.9231.6247204.3152.86
2.53.13.33.24.86.67.48.49.11013.514.115.916.918.420.32223.829.631.729.530.935.935.738.247.97093.4116.8120.3137.5122.5145.4194.5218.5241.39
000.1000000004.82.44.40.80.81.71.31.41.61.73.22227.10000000000
1.61.92.12.21.72.53.33.74.13.85.74.75.46.16.37.57.898.89.511.313.744.938.334.938.849.657.160.285.691.1103.2116.7141.1171.6179.73
0.20.20.30.40.711.221.822.52.93.34.75.25.86.46.98.39.210.114.46.81.51.512.217.87.613.310.718.124.316.922.927.143.43
5.36.57.811.7152127.833.339.857.250.886.3124.1129.2149.5128.1135149.8212.9258.3255.5201230.4346.5409.5469.4248.3253.9348398.4412.7520.9510.6605.5621.5617.42
0.71.41.81.93.74.44.3911.311.515.146.349.270.381.280.58988.891.5101.7100.197.495.493.8108.8117.1129.7132.4135.1145.3154248.3281.7288.8324.5342.44
000000000000004.491.35094.9115.6112.184191.7151.6145132.4140000000000
000000000000000000000000000000000000
0002.21.71.11.410.60.345.636.327.46.44.42.81.66.75.143252.346.540.6108.8292.8310.5452446.3579.4516.5616531.5534.6507.08
000000000000012.512.512.512.525.325.125.125.125.186.685.784.3151.5390.6430.9579597.9732.7728.3843.1822.1872.7972.66
000000.40.512.33.712.311.514.72011.210.27.154.764.41.51.31.82.61.71.91.9445.35.713.511.646.8285.3264.27
00000.010.010.010.010.010.020.070.090.090.110.110.20.160.220.240.250.220.320.390.370.370.390.820.881.211.191.471.511.751.692.022.09
0.010.010.010.020.020.030.030.040.050.070.120.180.220.240.260.330.30.370.450.510.470.520.620.720.780.861.061.131.561.591.882.032.262.292.642.7
                                                                       
0.10.10.10.10.10.10.10.10.20.20.20.40.40.40.40.40.40.40.40.40.40.40.40.40.40.40.40.40.40.40.40.40.40.41.61.58
2.22.42.65.98.18.18.511.412.613.734.552.957.458.663.36978.8101.9110115.4117.9122.5129.3131.9134.9147163.3178.8199.2246.6316.8420.5534.4653.7721.5820.34
0000.010.010.010.020.030.030.050.060.090.120.150.170.220.190.230.310.360.350.40.470.520.590.650.710.770.80.880.931.061.091.121.311.33
00.30.1000.10.10.10.40.50.1-0.5-1.30.13.15.33.65.712.912.1-7.5-21.2-16.9-20.7-24.3-8.5-45-64.9-67.9-69.5-83.5-97.2-57.3-75.2-66.1-78.32
00000000000000000000000.642.538.83.114.4-5.51924.7000000
000.010.010.020.020.030.040.050.060.10.140.180.210.240.30.270.340.440.490.460.50.590.670.740.80.850.880.951.081.171.381.561.71.972.07
1.81.92.10.811.82.22.62.13.17.98.79.710.84.83.94.15.46.96.17.59.65.213.66.29.713.420.716.918.516.223.129.433.925.737.97
0000.91.21.11.41.71.822.332.32.91.83.44.95.168.643.87.54.713.610.316.923.245.145.15549.778.291.862.887.62
0.10.10.20.60.20.50.60.712.23.203.1034.93.86.14.25.543.65.517.512.20.55.46.573.515.918.221.432.237.94033.79
0.10.1000000000000000000000005.90000000000
0.10.20.30.100000000.80.911.21.31.21.20000000043.80012.512.512.512.500
2.12.32.62.42.43.44.254.97.313.412.51614.710.813.51417.817.120.215.51718.235.83226.439.754.2135.579.5101.9106.7152.3176.1128.5159.38
0.50.80.52.1000000018.918.117.115.914.613.412.2000000077391.5343.8339492.7344.2328.8243.4350319
00000.10000000000000000013.49.18.533.861.462.8120.686.389.8101.193.1998955.86
0.50.30.20.10.10.30.40.50.91.713.57.83.9000000000000042.241.88.79.334.494.4117.575.4104.7100.78
11.10.72.20.20.30.40.50.91.713.526.72217.115.914.613.412.2000013.49.18.540.8176.6196.1473.1434.6616.9539.7539.4417.8543.7475.64
3.13.43.34.62.63.74.65.55.8926.939.23831.826.728.127.43017.120.215.51731.644.940.567.2216.3250.3608.6514.1718.8646.4691.7593.9672.2635.02
0.010.010.010.020.020.030.030.040.050.070.120.180.220.240.260.330.30.370.450.510.470.520.620.720.780.861.061.131.561.591.882.032.252.32.642.7
Details

Balance Sheet

Understanding the Balance Sheet

The balance sheet of Bio-Techne provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Bio-Techne's financial health and stability.

Assets

Bio-Techne's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Bio-Techne must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Bio-Techne after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Bio-Techne's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)
DEPRECIATION (M)
DEFERRED TAXES (M)
CHANGES IN WORKING CAPITAL (M)
NON-CASH ITEM (M)
PAID INTEREST (M)
PAID TAXES (M)
NET CASH FLOW FROM OPERATING ACTIVITIES (M)
CAPITAL EXPENDITURES (M)
CASH FLOW FROM INVESTING ACTIVITIES (M)
CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)
INTEREST INCOME AND EXPENSES (M)
NET DEBT CHANGE (M)
NET CHANGE IN EQUITY (M)
CASH FLOW FROM FINANCING ACTIVITIES (M)
CASH FLOW FROM OTHER FINANCING ACTIVITIES (M)
TOTAL DIVIDENDS PAID (M)
NET CHANGE IN CASH FLOW (M)
FREE CASH FLOW (M)
SHARE-BASED COMPENSATION (M)
19891990199119921993199419951996199719981999200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023
0112456810151626342745526673851031051091121121121101071047612696229139263285
00011111221112121266677778812121937426064788287101107
0000000-100-1-10-60000000-13-7-2-21-2-3-46-1313-276-29
0000-10-1002010-801112-32-4-70-3-5-1-11-15-151-27-529-69-90
00000001012002340-534434148141024415280-821716521
000000000001111000100000001179211813118
00012223569972117262627464950494658510424442353642213088
011346791220283846275565748590115111111127126123136139144143170181205352325254
0000-2-1-1-6-4-2-5-30-6-22-15-3-11-4-8-16-6-4-3-6-22-13-19-16-15-20-25-51-44-44-38
000-1-5-4-7-7-8-4-38-60-40-22-21-5953-70-39-2721-114-114-21-3149-426-107-306-38-33627-243-96-265
0000-2-3-5-1-4-1-33-29-330-6-5564-66-31-1127-110-110-15-863-406-90-290-17-31178-199-51-227
00000000000000000000000000000000000
000000000001900-1-1-1-1-1300000006818252-4166-148-15-8594
00000000-20-2600-214-95-141-57-91-122-23-1895519222021-8310
00000000-20-226-1-1-222-97-7-11-56-119-50-36-64-44-3631-23189-99134-183-62-24222
0000000000000000080000000000-20-65-6-7-19-23-31
00000000000000000000-28-38-39-41-43-45-47-47-47-48-48-48-49-50-50
00020102117-1343512112994531-6-66-163947154-26492730-214552-268
00.70.93.41.955.43.48.318.122.88.339.65.44061.9638182.498.9104.7106.7123.6120.7101.1123119.5127.3128.5149.5156.2153.5307.9280.4216.2
00000000000000000000000000000000000

Bio-Techne stock margins

The Bio-Techne margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Bio-Techne. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Bio-Techne.
  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Details

Margin

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Bio-Techne's sales revenue. A higher gross margin percentage indicates that the Bio-Techne retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Bio-Techne's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Bio-Techne's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Bio-Techne's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Bio-Techne. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Bio-Techne's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Bio-Techne Margin History

Bio-Techne Gross marginBio-Techne Profit marginBio-Techne EBIT marginBio-Techne Profit margin
2031e66.41 %0 %0 %
2030e66.41 %42.78 %26.8 %
2029e66.41 %37.8 %28.49 %
2028e66.41 %33.86 %28.3 %
2027e66.41 %32.94 %27.08 %
2026e66.41 %31.79 %26.07 %
2025e66.41 %30.97 %25.27 %
202466.41 %21.44 %14.5 %
202367.72 %25.83 %25.09 %
202268.42 %26.97 %24.59 %
202167.98 %26.31 %15.07 %
202065.41 %20.4 %31.01 %
201966.32 %20.87 %13.45 %
201867.2 %25.04 %19.63 %
201766.52 %26 %13.52 %
201667.47 %30.74 %20.94 %
201567.96 %33.5 %23.82 %
201470.26 %44.66 %30.99 %
201374.4 %51.03 %36.25 %
201275.91 %54.2 %35.7 %
201177.86 %57.17 %38.72 %
201079.59 %58.1 %40.82 %
200978.79 %57.12 %39.85 %
200879.45 %56.06 %40.25 %
200779.11 %55.57 %38.08 %
200677.44 %53.55 %36.23 %
200579.35 %54.73 %36.99 %

Bio-Techne Stock Sales Revenue, EBIT, Earnings per Share

The Bio-Techne earnings per share therefore indicates how much revenue Bio-Techne has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.
  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details
Details

Revenue, EBIT and Earnings per share

Revenue Per Share

Revenue per share represents the total revenue Bio-Techne earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Bio-Techne's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Bio-Techne’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Bio-Techne's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Bio-Techne Revenue, EBIT and net profit per share

DateBio-Techne Sales per ShareBio-Techne EBIT per shareBio-Techne Earnings per Share
2031e13.6 undefined0 undefined0 undefined
2030e10.88 undefined0 undefined2.92 undefined
2029e9.85 undefined0 undefined2.81 undefined
2028e9.36 undefined0 undefined2.65 undefined
2027e8.9 undefined0 undefined2.41 undefined
2026e8.14 undefined0 undefined2.12 undefined
2025e7.72 undefined0 undefined1.95 undefined
20247.21 undefined1.55 undefined1.05 undefined
20237.02 undefined1.81 undefined1.76 undefined
20226.74 undefined1.82 undefined1.66 undefined
20215.75 undefined1.51 undefined0.87 undefined
20204.69 undefined0.96 undefined1.45 undefined
20194.59 undefined0.96 undefined0.62 undefined
20184.22 undefined1.06 undefined0.83 undefined
20173.75 undefined0.98 undefined0.51 undefined
20163.34 undefined1.03 undefined0.7 undefined
20153.04 undefined1.02 undefined0.72 undefined
20142.42 undefined1.08 undefined0.75 undefined
20132.1 undefined1.07 undefined0.76 undefined
20122.13 undefined1.15 undefined0.76 undefined
20111.95 undefined1.11 undefined0.76 undefined
20101.8 undefined1.05 undefined0.73 undefined
20091.74 undefined0.99 undefined0.69 undefined
20081.64 undefined0.92 undefined0.66 undefined
20071.41 undefined0.79 undefined0.54 undefined
20061.28 undefined0.68 undefined0.46 undefined
20051.09 undefined0.6 undefined0.4 undefined

Bio-Techne business model

Bio-Techne Corp is a global company specializing in the research and development of innovative products and solutions in the field of biosciences. The company was founded in 1976 in Minneapolis and was formerly known as Techne Corporation. Since then, it has grown into an internationally renowned company through its numerous acquisitions and mergers. The company is headquartered in Minneapolis, Minnesota, USA. The business philosophy of Bio-Techne Corp is to help bioscientific researchers and clinicians around the world perform their work more effectively, efficiently, and quickly. The company works closely with its customers to provide them with suitable products and services, thereby developing innovative solutions to the challenges in bioscience. Bio-Techne Corp has various business segments, including protein platforms, diagnostics, genetic analysis, clinical controls, cell culture products, and research reagents. Each business segment offers a variety of products and services to support researchers and clinicians in their work. A key business segment of Bio-Techne Corp is the protein platform, which offers a comprehensive range of proteins, antibodies, and corresponding detection reagents. The company is known for its high-quality proteins and antibodies, which contribute to improving the research of diseases such as cancer, diabetes, and neurological and immunological disorders. Another important business segment of Bio-Techne Corp is diagnostics. Here, the company offers a wide range of clinical diagnostic products, such as tests for analyzing urea, creatinine, and bone density. The company's products help clinicians make precise diagnoses and treat patients more effectively. The genetic analysis segment offers DNA sequencing, gene expression, and genome-wide analysis products and services. These tools enable researchers to better understand the functioning of the human body by exploring the underlying genetic changes. The clinical controls segment offers product and service offerings that improve the reliability and accuracy of diagnostic systems. The company works closely with medical facilities to provide diagnostic solutions that deliver fast and accurate results. The cell culture products segment offers a complete range of solutions for cell cultivation and growth. The offering ranges from basic nutrient media and additives to culture vessels and accessories. The company's products enable researchers to culture cells in a controlled environment and under precise conditions. The last segment of Bio-Techne Corp includes research reagents. Here, the company offers a wide range of reagents used for protein, antibody, and cell function analysis and research. The products meet the needs of researchers in modern bioscience. In summary, Bio-Techne Corp is a company specialized in developing innovative solutions in bioscience, advancing science and medicine. With its products and services offered in various sectors, the company successfully helps researchers and clinicians perform their work faster, more effectively, and cost-efficiently. Bio-Techne is one of the most popular companies on Eulerpool.com.

Bio-Techne SWOT Analysis

Strengths

[ { "heading": "1.", "text": "Strong" }, { "heading": "2.", "text": "Robust" }, { "heading": "3.", "text": "Established" }, { "heading": "4.", "text": "Strong" } ]

Weaknesses

[ { "heading": "1.", "text": "Reliance" }, { "heading": "2.", "text": "Limited" }, { "heading": "3.", "text": "High" }, { "heading": "4.", "text": "Potential" } ]

Opportunities

[ { "heading": "1.", "text": "Growing" }, { "heading": "2.", "text": "Expansion" }, { "heading": "3.", "text": "Acquisitions" }, { "heading": "4.", "text": "Increasing" } ]

Threats

[ { "heading": "1.", "text": "Economic" }, { "heading": "2.", "text": "Intellectual" }, { "heading": "3.", "text": "Rapid" }, { "heading": "4.", "text": "Regulatory" } ]

Eulerpool Premium

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Bio-Techne Eulerpool Fair Value

Details

Fair Value

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Bio-Techne historical P/E ratio, EBIT multiple, and P/S ratio

Eulerpool Premium

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Bio-Techne shares outstanding

The number of shares was Bio-Techne in 2024 — This indicates how many shares 160.774 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.
  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details
Details

Revenue, EBIT and Earnings per share

Revenue Per Share

Revenue per share represents the total revenue Bio-Techne earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Bio-Techne's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Bio-Techne’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Bio-Techne's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Bio-Techne stock splits

In Bio-Techne's history, there have been no stock splits.

Bio-Techne dividend history and estimates

In 2024, Bio-Techne paid a dividend amounting to 0.4 undefined. Dividend means that Bio-Techne distributes a portion of its profits to its owners.
  • Max

Dividend
Dividend (Estimate)
Details
Details

Dividend

Dividend Overview

The dividend per year chart for Bio-Techne provides a comprehensive view of the annual dividends distributed to shareholders. Analyze the trend to understand the consistency and growth in dividend payouts over the years.

Interpretation and Use

A consistent or increasing trend in dividends can indicate the company's profitability and financial health. Investors can use this data to identify Bio-Techne’s potential for long-term investment and income generation through dividends.

Investment Strategy

Incorporate the dividend data in evaluating Bio-Techne's overall performance. A thorough analysis, considering other financial aspects, will help in making informed investment decisions for optimal capital growth and income generation.

Bio-Techne Dividend History

DateBio-Techne Dividend
2030e1.11 undefined
2029e1.07 undefined
2028e0.98 undefined
2027e0.94 undefined
2026e0.82 undefined
2009e0.06 undefined
20250.32 undefined
20240.4 undefined
20230.32 undefined
20220.32 undefined
20210.32 undefined
20200.32 undefined
20190.32 undefined
20180.32 undefined
20170.32 undefined
20160.32 undefined
20150.32 undefined
20140.31 undefined
20130.3 undefined
20120.28 undefined
20110.27 undefined
20100.26 undefined
2009e0.19 undefined

Bio-Techne dividend payout ratio

In 2024, Bio-Techne had a payout ratio of 43.88%. The payout ratio indicates the percentage of the company's profits that Bio-Techne distributes as dividends.
  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Payout ratio
Details
Details

Payout ratio

What is Yearly Payout Ratio?

The yearly payout ratio for Bio-Techne represents the proportion of earnings paid out as dividends to shareholders. It is an indicator of the company's financial health and stability, illustrating how much profit is being returned to investors versus being reinvested back into the company.

How to Interpret the Data

A lower payout ratio for Bio-Techne could mean that the company is reinvesting more into its growth, whereas a higher ratio indicates more earnings are being distributed as dividends. Investors seeking regular income might prefer companies with a higher payout ratio, while those looking for growth may opt for companies with a lower ratio.

Using the Data for Investments

Evaluate Bio-Techne's payout ratio in conjunction with other financial metrics and performance indicators. A sustainable payout ratio, coupled with strong financial health, can indicate a reliable dividend payout. However, a very high ratio might suggest the company is not sufficiently reinvesting in its future growth.

Bio-Techne Payout Ratio History

DateBio-Techne Payout ratio
2031e37.84 %
2030e38.09 %
2029e38.26 %
2028e37.17 %
2027e38.85 %
2026e38.75 %
2025e33.93 %
202443.88 %
202338.43 %
202219.47 %
202173.75 %
202022.07 %
201951.61 %
201839.02 %
201762.75 %
201691.43 %
201544.44 %
201441.67 %
201339.8 %
201237.5 %
201135.86 %
201035.96 %
200936.59 %
20089.47 %
200738.43 %
200638.43 %
200538.43 %
Eulerpool Premium

The World’s Best Investors Are On Eulerpool

Subscribe for $2
Unfortunately, there are currently no price targets and forecasts available for Bio-Techne.

Bio-Techne latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
6/30/20250.51 0.53  (4.15 %)2025 Q4
3/31/20250.52 0.56  (7.36 %)2025 Q3
12/31/20240.39 0.42  (6.57 %)2025 Q2
9/30/20240.39 0.42  (7.75 %)2025 Q1
6/30/20240.5 0.49  (-2.78 %)2024 Q4
3/31/20240.46 0.48  (3.92 %)2024 Q3
12/31/20230.42 0.4  (-4.94 %)2024 Q2
9/30/20230.44 0.41  (-7.66 %)2024 Q1
6/30/20230.56 0.55  (-1.4 %)2023 Q4
3/31/20230.54 0.53  (-1.6 %)2023 Q3
1
2
3
4
5
...
12

Eulerpool ESG Scorecard© for the Bio-Techne stock

Eulerpool World ESG Rating (EESG©)

72/ 100

🌱 Environment

59

👫 Social

99

🏛️ Governance

57

Environment

Scope 1 - Direct Emissions
Scope 2 - Indirect emissions from purchased energy
Scope 3 - Indirect emissions within the value chain
Total CO₂ emissions
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather
Pesticides
Palm Oil
Tobacco
Genetically modified organisms
Climate concept
Sustainable forestry
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency

Social

Percentage of female employees49
Percentage of women in management
Percentage of Asian employees
Share of Asian management
Percentage of Hispanic/Latino employees
Hispano/Latino Management share
Percentage of Black employees
Black Management Share
Percentage of white employees61
White Management Share74
Adult content
Alcohol
Weapons
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept
Occupational health and safety
Catholic

Governance (Corporate Governance)

Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Bio-Techne shareholders

%
Name
Stocks
Change
Date
11.44321 % The Vanguard Group, Inc.18,397,700-60,8336/30/2025
5.46931 % BlackRock Institutional Trust Company, N.A.8,793,227-512,2576/30/2025
5.35924 % T. Rowe Price Associates, Inc.8,616,270-2,527,9516/30/2025
3.64399 % State Street Global Advisors (US)5,858,583-671,3046/30/2025
2.67096 % Atlanta Capital Management Company, L.L.C.4,294,202573,2286/30/2025
2.52684 % Geode Capital Management, L.L.C.4,062,509-30,8896/30/2025
2.01449 % Invesco Capital Management LLC3,238,773274,9576/30/2025
1.81590 % Select Equity Group, L.P.2,919,495-2,446,5086/30/2025
1.78342 % Mairs and Power, Inc.2,867,26968,9196/30/2025
1.73856 % Baron Capital Management, Inc.2,795,147-480,6596/30/2025
1
2
3
4
5
...
10

Bio-Techne Executives and Management Board

Mr. Kim Kelderman

(57)
Bio-Techne President, Chief Executive Officer, Chief Operating Officer, Director (since 2018)
Compensation 6.85 M

Mr. James Hippel

(52)
Bio-Techne Chief Financial Officer, Executive Vice President - Finance
Compensation 5.2 M

Mr. William Geist

(53)
Bio-Techne President - Protein Sciences
Compensation 3.65 M

Dr. Matthew Mcmanus

(55)
Bio-Techne President - Diagnostics and Genomics Segment
Compensation 1.99 M

Mr. Shane Bohnen

(49)
Bio-Techne Senior Vice President, General Counsel, Corporate Secretary
Compensation 1.46 M
1
2
3

Bio-Techne Supply Chain

NameRelationshipTwo-week correlationOne-month correlationThree-Month CorrelationSix-Month CorrelationOne Year CorrelationTwo-Year Correlation
SupplierCustomer0,810,880,890,850,75
SupplierCustomer0,760,810,800,830,380,77
SupplierCustomer0,650,840,960,890,830,90
SupplierCustomer0,600,800,790,860,79
SupplierCustomer0,410,780,760,740,88
SupplierCustomer0,370,620,840,650,64-0,17
SupplierCustomer0,350,620,810,700,58-0,01
SupplierCustomer0,110,500,740,750,57
SupplierCustomer-0,140,420,790,55-0,080,79
SupplierCustomer-0,190,410,750,660,660,68
1
2

Most common questions regarding Bio-Techne

What values and corporate philosophy does Bio-Techne represent?

Bio-Techne Corp is a leading global provider of life science products and solutions. The company values innovation, scientific excellence, and customer-centricity. Bio-Techne Corp's corporate philosophy revolves around advancing scientific discoveries and improving human health. With a strong commitment to research and development, Bio-Techne Corp focuses on providing cutting-edge tools and technologies to support the life science community. By fostering collaboration and investing in breakthrough technologies, the company aims to accelerate scientific progress and enable researchers to make significant contributions in the fields of genomics, proteomics, and cell biology. Overall, Bio-Techne Corp is dedicated to driving innovation and making a positive impact in the life science industry.

In which countries and regions is Bio-Techne primarily present?

Bio-Techne Corp is primarily present in various countries and regions worldwide. The company has a widespread global presence, with significant operations and a strong market presence in North America, Europe, and Asia-Pacific. This enables Bio-Techne Corp to serve a diverse customer base and tap into multiple international markets. Along with its headquarters in the United States, Bio-Techne Corp has strategic offices, production facilities, and distribution networks across key countries and regions globally. This expansive global footprint allows the company to effectively deliver its innovative biotechnology solutions and services to customers around the world.

What significant milestones has the company Bio-Techne achieved?

Bio-Techne Corp has achieved several significant milestones. The company has successfully expanded its product portfolio, offering a wide range of innovative solutions in life sciences research and diagnostics. Bio-Techne Corp has also witnessed strong financial performance, consistently delivering impressive revenue growth over the years. Moreover, the company has made strategic acquisitions to enhance its capabilities and market presence. With a focus on advanced technologies and a commitment to innovation, Bio-Techne Corp continues to contribute to scientific advancements and improve healthcare outcomes globally.

What is the history and background of the company Bio-Techne?

Bio-Techne Corp, formerly known as Techne Corporation, is a leading global life sciences company. Established in 1976, Bio-Techne has a rich history of innovation and scientific discovery. The company develops and manufactures a wide range of cutting-edge products and solutions for the biotechnology and clinical research industries. With a strong focus on research and development, Bio-Techne has consistently brought forth groundbreaking technologies and advanced tools, revolutionizing the understanding and treatment of diseases. Today, Bio-Techne Corp remains at the forefront of the life sciences industry, delivering high-quality products and driving advancements in scientific research worldwide.

Who are the main competitors of Bio-Techne in the market?

Some of the main competitors of Bio-Techne Corp in the market include Thermo Fisher Scientific, Merck KGaA, and Agilent Technologies.

In which industries is Bio-Techne primarily active?

Bio-Techne Corp primarily operates in the biotechnology and life sciences industries. Its extensive product portfolio includes cutting-edge solutions for research and diagnostics, spanning the fields of pharmaceuticals, clinical applications, bioprocessing, and academia. With a focus on developing innovative technologies, Bio-Techne Corp delivers products and services that support advancements in areas such as cancer research, stem cell research, immunology, neuroscience, and genetic analysis. As a leading player in these sectors, Bio-Techne Corp continues to make significant contributions to the scientific community and drive progress in the biotechnology field.

What is the business model of Bio-Techne?

Bio-Techne Corp's business model revolves around providing innovative life science tools and solutions to researchers worldwide. The company focuses on developing and manufacturing high-quality reagents, assays, and instruments used in biomedical research, clinical diagnostics, and pharmaceutical development. With a diverse portfolio, Bio-Techne offers products for gene expression analysis, protein analysis, cell imaging, and stem cell research. Their advanced technologies and expertise enable scientists to accelerate discoveries and enhance their understanding of diseases, ultimately aiding in the development of new therapies. Bio-Techne Corp strives to be at the forefront of scientific advancements by continually investing in research and development initiatives.

What is the P/E ratio of Bio-Techne 2025?

The P/E ratio cannot be calculated for Bio-Techne at the moment.

What is the P/S ratio of Bio-Techne 2025?

The P/S cannot be calculated for Bio-Techne currently.

What is the Quality Investing of Bio-Techne?

The Quality Investing for Bio-Techne is 6/10.

What is the revenue of Bio-Techne 2025?

The expected Bio-Techne revenue is 1.24 B USD.

How high is the profit of Bio-Techne 2025?

The expected Bio-Techne profit is 313.56 M USD.

What is the business model of Bio-Techne

Bio-Techne Corp is a leading provider of innovative products for the biotechnology and clinical diagnostics industry. The company offers a wide range of products and services for protein research, cell analysis, microscopy, genomics, and clinical diagnostics. Protein research: Bio-Techne offers proteins, antibodies, reagents, and instruments for signal pathway research, protein expression, and function. Well-known brands in this field include R&D Systems, Novus Biologicals, Tocris, and ProteinSimple. Cell analysis: For cell analysis, Bio-Techne provides a wide range of products including cell analysis devices, reagents, and instruments for flow cytometry, cell culture, and microscopy. BioLegend is the leading brand for cell analysis products from Bio-Techne. Microscopy: Bio-Techne also offers a wide range of microscopy products for cell and tissue analysis. This includes endoscopes, cameras, microscopes, imaging software, and accessories. Brands in this field include Nikon Instruments, Zeiss, and Lumera. Genomics: Bio-Techne's genomics offering includes custom gene synthesis, antisense oligonucleotides, miRNA inhibitors, as well as PCR, qPCR, and sequencing kits and reagents. The company also provides comprehensive genomics services including analysis, sequencing, and data analysis. Clinical diagnostics: Bio-Techne provides solutions for clinical diagnostics, including IVD reagents, custom biomarker development and services, immunohistochemistry test systems, as well as devices and instruments for clinical sample submission. Brands in this field include R&D Systems, Novus Biologicals, and Exosome Diagnostics. Summary: Overall, Bio-Techne Corp offers a wide range of solutions for the biotechnology and clinical diagnostics industry. With its leading brands and extensive range of products and services, the company has established itself as a key player in this field. Through continuous product and service development and innovation, Bio-Techne is able to maintain its market share and further expand its business in various niche markets.

What is the Bio-Techne dividend?

Bio-Techne pays a dividend of 0.32 USD distributed over 4 payouts per year.

How often does Bio-Techne pay dividends?

Bio-Techne pays out a dividend 4 times a year.

What is the Bio-Techne ISIN?

The ISIN of Bio-Techne is US09073M1045.

What is the Bio-Techne WKN?

The WKN of Bio-Techne is A12ENG.

What is the Bio-Techne ticker?

The ticker of Bio-Techne is TECH.

How much dividend does Bio-Techne pay?

Over the past 12 months, Bio-Techne paid a dividend of 0.4 USD . This corresponds to a dividend yield of about . For the coming 12 months, Bio-Techne is expected to pay a dividend of 0.82 USD.

What is the dividend yield of Bio-Techne?

The current dividend yield of Bio-Techne is .

When does Bio-Techne pay dividends?

Bio-Techne pays a quarterly dividend. This is distributed in the months of December, March, June, September.

How secure is the dividend of Bio-Techne?

Bio-Techne paid dividends every year for the past 0 years.

What is the dividend of Bio-Techne?

For the upcoming 12 months, dividends amounting to 0.82 USD are expected. This corresponds to a dividend yield of 1.51 %.

In which sector is Bio-Techne located?

Bio-Techne is assigned to the 'Health' sector.

Wann musste ich die Aktien von Bio-Techne kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Bio-Techne from 8/29/2025 amounting to 0.08 USD, you needed to have the stock in your portfolio before the ex-date on 8/18/2025.

When did Bio-Techne pay the last dividend?

The last dividend was paid out on 8/29/2025.

What was the dividend of Bio-Techne in the year 2024?

In the year 2024, Bio-Techne distributed 0.32 USD as dividends.

In which currency does Bio-Techne pay out the dividend?

The dividends of Bio-Techne are distributed in USD.

All fundamentals about Bio-Techne

Our stock analysis for Bio-Techne Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Bio-Techne Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.